{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:54:02Z","timestamp":1793256842092,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Municipal Education Commission Grant Support","award":["2023ZKZD23"],"award-info":[{"award-number":["2023ZKZD23"]}]},{"name":"Shanghai Municipal Education Commission Grant Support","award":["20221810"],"award-info":[{"award-number":["20221810"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"crossref","award":["2019LJ11"],"award-info":[{"award-number":["2019LJ11"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ren Ji Hospital","award":["RJLJHZ-02"],"award-info":[{"award-number":["RJLJHZ-02"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373358"],"award-info":[{"award-number":["82373358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172868"],"award-info":[{"award-number":["82172868"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer with limited therapeutic options. Although cisplatin is recommended as a first-line treatment, its clinical efficacy is hindered by the rapid development of drug resistance, highlighting the urgent need for effective strategies to overcome cisplatin resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established a NEPC mouse allograft model and performed RNA sequencing to identify genes associated with cisplatin resistance. The role of CCL5 in tumor-stromal crosstalk was investigated using immunofluorescence, ELISA assays, co-culture assays, and CCL5 knockout mice. Mechanistic studies were conducted to explore CCL5\/CCR5-mediated signaling pathways. The therapeutic efficacy of cisplatin combined with maraviroc, an FDA-approved CCR5 antagonist, was evaluated in vitro using NEPC cell lines and patient-derived organoids, and in vivo using NEPC mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we identify a tumor-stromal interaction mediated by the CCL5\/CCR5 axis that drives cisplatin resistance in NEPC. Cisplatin-induced DNA damage promotes a cGAS-STING\u2013dependent senescence program in cancer-associated fibroblasts (CAFs), resulting in the secretion of CCL5, a key senescence-associated secretory phenotype factor. CCL5 from CAFs binds to CCR5 on tumor cells, promoting the formation of a CCR5\/\u03b2-arrestin1\/p85 complex that activates the PI3K\/AKT pathway. This activation enhances DNA repair, protecting tumor cells from cisplatin-induced apoptosis. Pharmacologic inhibition of the CCL5\/CCR5 pathway using maraviroc, an FDA-approved CCR5 antagonist, sensitizes NEPC cells to cisplatin treatment and significantly prolongs survival in NEPC mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify the CCL5\/CCR5 axis as a key mediator of tumor-stromal crosstalk driving cisplatin resistance in NEPC. Mechanistically, CAF-derived CCL5 activates AKT signaling in tumor cells by promoting the formation of the CCR5\/\u03b2-arrestin1\/p85 complex. Targeting this pathway with maraviroc in combination with cisplatin offers a promising therapeutic strategy for overcoming drug resistance in NEPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03552-y","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:55:35Z","timestamp":1761659735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the CCL5\/CCR5 axis in tumor-stromal crosstalk to overcome cisplatin resistance in neuroendocrine prostate cancer"],"prefix":"10.1186","volume":"44","author":[{"given":"Bo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruopeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"1","key":"3552_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"3552_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"key":"3552_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"3552_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"3552_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL. Cancer-associated fibroblasts in Gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019;16(5):282\u201395.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"3552_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, Li B, Wang H, Miyake T, Correa de Sampaio P, et al. Identification of functional heterogeneity of Carcinoma-Associated fibroblasts with distinct IL6-Mediated therapy resistance in pancreatic cancer. Cancer Discov. 2022;12(6):1580\u201397.","journal-title":"Cancer Discov"},{"issue":"2","key":"3552_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7150\/thno.87329","volume":"14","author":"SH Kang","year":"2024","unstructured":"Kang SH, Oh SY, Lee KY, Lee HJ, Kim MS, Kwon TG, Kim JW, Lee ST, Choi SY, Hong SH. Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p. Theranostics. 2024;14(2):460\u201379.","journal-title":"Theranostics"},{"issue":"1","key":"3552_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24(1):28\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3552_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11(4):213\u20139.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"3552_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346\u201360. e347.","journal-title":"Cancer Cell"},{"issue":"6320","key":"3552_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang ZD, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer. Science. 2017;355(6320):84\u20138.","journal-title":"Science"},{"issue":"1","key":"3552_CR12","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1038\/s41467-023-43676-3","volume":"14","author":"Y Ji","year":"2023","unstructured":"Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, et al. The ELAVL3\/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer. Nat Commun. 2023;14(1):7794.","journal-title":"Nat Commun"},{"issue":"4","key":"3552_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"JK Lee","year":"2016","unstructured":"Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 2016;29(4):536\u201347.","journal-title":"Cancer Cell"},{"issue":"10","key":"3552_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D\u2019Amico AV, et al. Prostate Cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"3552_CR15","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1038\/s41467-019-11729-1","volume":"10","author":"Q Wang","year":"2019","unstructured":"Wang Q, Guldner IH, Golomb SM, Sun L, Harris JA, Lu X, Zhang S. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4\/6 inhibitor-resistant HER2-positive breast cancer. Nat Commun. 2019;10(1):3817.","journal-title":"Nat Commun"},{"issue":"1","key":"3552_CR16","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","volume":"11","author":"M Strunz","year":"2020","unstructured":"Strunz M, Simon LM, Ansari M, Kathiriya JJ, Angelidis I, Mayr CH, Tsidiridis G, Lange M, Mattner LF, Yee M, et al. Alveolar regeneration through a Krt8\u2009+\u2009transitional stem cell state that persists in human lung fibrosis. Nat Commun. 2020;11(1):3559.","journal-title":"Nat Commun"},{"issue":"9","key":"3552_CR17","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","volume":"48","author":"S Detre","year":"1995","unstructured":"Detre S, Saclani Jotti G, Dowsett M. A quickscore method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876\u20138.","journal-title":"J Clin Pathol"},{"issue":"4","key":"3552_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"4","key":"3552_CR19","doi-asserted-by":"publisher","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300(4):C723\u2013742.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"3552_CR20","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, Shen K, Pan J, Wang Q, Xue W. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022;12(11):4965\u201379.","journal-title":"Theranostics"},{"issue":"3","key":"3552_CR21","doi-asserted-by":"publisher","first-page":"112188","DOI":"10.1016\/j.celrep.2023.112188","volume":"42","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, He B, Zhang D, Zhang Y, Chen C, Zhang W, Yang S, Yao M, Cui G, Gu J, et al. FAK-mediated phosphorylation at Y464 regulates p85\u03b2 nuclear translocation to promote tumorigenesis of CcRCC by repressing RB1 expression. Cell Rep. 2023;42(3):112188.","journal-title":"Cell Rep"},{"issue":"1","key":"3552_CR22","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, Pignolo RJ, Robbins PD, Niedernhofer LJ, Ikeno Y, et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat Commun. 2022;13(1):4827.","journal-title":"Nat Commun"},{"key":"3552_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-1-4939-9086-3_17","volume":"1940","author":"Y Shu","year":"2019","unstructured":"Shu Y, Chua CW. An organoid assay for Long-Term maintenance and propagation of mouse prostate luminal epithelial progenitors and cancer cells. Methods Mol Biol. 2019;1940:231\u201354.","journal-title":"Methods Mol Biol"},{"issue":"6320","key":"3552_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbe DP, Gomez EC, Wang J, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78\u201383.","journal-title":"Science"},{"key":"3552_CR25","doi-asserted-by":"publisher","first-page":"175883592211283","DOI":"10.1177\/17588359221128356","volume":"14","author":"C Chi","year":"2022","unstructured":"Chi C, Liu J, Fan L, Zhu Y, Wang Y, Sha J, Huang Y, Dong B, Pan J, Xue W. Efficacy of neoadjuvant docetaxel\u2009+\u2009cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. Ther Adv Med Oncol. 2022;14:17588359221128356.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"3552_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21(9):501\u201321.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"26","key":"3552_CR27","doi-asserted-by":"publisher","first-page":"27199","DOI":"10.1074\/jbc.M403107200","volume":"279","author":"MI Wickremasinghe","year":"2004","unstructured":"Wickremasinghe MI, Thomas LH, O\u2019Kane CM, Uddin J, Friedland JS. Transcriptional mechanisms regulating alveolar epithelial Cell-specific CCL5 secretion in pulmonary Tuberculosis*. J Biol Chem. 2004;279(26):27199\u2013210.","journal-title":"J Biol Chem"},{"issue":"1","key":"3552_CR28","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.celrep.2020.03.056","volume":"31","author":"KR Balka","year":"2020","unstructured":"Balka KR, Louis C, Saunders TL, Smith AM, Calleja DJ, D\u2019Silva DB, Moghaddas F, Tailler M, Lawlor KE, Zhan Y, et al. TBK1 and IKK\u03b5 act redundantly to mediate STING-Induced NF-\u03baB responses in myeloid cells. Cell Rep. 2020;31(1):107492.","journal-title":"Cell Rep"},{"issue":"1","key":"3552_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/sj.cr.7290203","volume":"14","author":"W Zhao","year":"2004","unstructured":"Zhao W, Lin ZX, Zhang ZQ. Cisplatin-induced premature senescence with concomitant reduction of gap junctions in human fibroblasts. Cell Res. 2004;14(1):60\u20136.","journal-title":"Cell Res"},{"issue":"5","key":"3552_CR30","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287\u201399.","journal-title":"J Exp Med"},{"issue":"7713","key":"3552_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","volume":"559","author":"SM Haag","year":"2018","unstructured":"Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559(7713):269\u201373.","journal-title":"Nature"},{"key":"3552_CR32","doi-asserted-by":"crossref","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 axis in cancer progression. Cancers (Basel). 2020;12(7):1765.","DOI":"10.3390\/cancers12071765"},{"issue":"2","key":"3552_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","volume":"22","author":"V Appay","year":"2001","unstructured":"Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol. 2001;22(2):83\u20137.","journal-title":"Trends Immunol"},{"issue":"1","key":"3552_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bjh.12226","volume":"161","author":"J Udi","year":"2013","unstructured":"Udi J, Sch\u00fcler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, Schnerch D, Follo M, W\u00e4sch R, Engelhardt M. Potent in vitro and in vivo activity of Sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and Inhibition of migration through actin depolymerization. Br J Haematol. 2013;161(1):104\u201316.","journal-title":"Br J Haematol"},{"issue":"6152","key":"3552_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor Maraviroc complex. Science. 2013;341(6152):1387\u201390.","journal-title":"Science"},{"key":"3552_CR36","doi-asserted-by":"publisher","first-page":"101014","DOI":"10.1016\/j.drup.2023.101014","volume":"71","author":"Y Hu","year":"2023","unstructured":"Hu Y, Xu Y, Zhang T, Han Q, Li L, Liu M, Li N, Shao G. Cisplatin-activated ER\u03b2\/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN\/Akt axis. Drug Resist Updat. 2023;71:101014.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3552_CR37","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-023-38318-7","volume":"14","author":"SJ Oh","year":"2023","unstructured":"Oh SJ, Lim JY, Son MK, Ahn JH, Song KH, Lee HJ, Kim S, Cho EH, Chung JY, Cho H, et al. TRPV1 Inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway. Nat Commun. 2023;14(1):2691.","journal-title":"Nat Commun"},{"issue":"11","key":"3552_CR38","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","volume":"16","author":"M Oppermann","year":"2004","unstructured":"Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16(11):1201\u201310.","journal-title":"Cell Signal"},{"issue":"7","key":"3552_CR39","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","volume":"78","author":"X Jiao","year":"2018","unstructured":"Jiao X, Velasco-Velazquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018;78(7):1657\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"3552_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0304-3835(02)00615-8","volume":"190","author":"KM Nicholson","year":"2003","unstructured":"Nicholson KM, Quinn DM, Kellett GL, Warr JR. LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes Preferential induction of apoptosis in human multidrug resistant cells. Cancer Lett. 2003;190(1):31\u20136.","journal-title":"Cancer Lett"},{"issue":"4","key":"3552_CR41","doi-asserted-by":"publisher","first-page":"E577","DOI":"10.1210\/jc.2010-2644","volume":"96","author":"R Liu","year":"2011","unstructured":"Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K\/Akt pathway. J Clin Endocrinol Metab. 2011;96(4):E577\u2013585.","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"3552_CR42","doi-asserted-by":"publisher","first-page":"e2110085119","DOI":"10.1073\/pnas.2110085119","volume":"119","author":"A Mafi","year":"2022","unstructured":"Mafi A, Kim SK, Goddard WA. 3rd: the mechanism for ligand activation of the GPCR-G protein complex. Proc Natl Acad Sci U S A. 2022;119(18):e2110085119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3552_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","volume":"25","author":"D Hilger","year":"2018","unstructured":"Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25(1):4\u201312.","journal-title":"Nat Struct Mol Biol"},{"key":"3552_CR44","doi-asserted-by":"crossref","unstructured":"Isaikina P, Petrovic I, Jakob RP, Sarma P, Ranjan A, Baruah M, Panwalkar V, Maier T, Shukla AK, Grzesiek S. A key GPCR phosphorylation motif discovered in arrestin2\u22c5CCR5 phosphopeptide complexes. Mol Cell. 2023.","DOI":"10.1101\/2022.10.10.511578"},{"issue":"1","key":"3552_CR45","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1038\/s41467-021-24438-5","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen K, Tan Q, Shao Q, Han S, Zhang C, Yi C, Chu X, Zhu Y, Xu Y, et al. Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5. Nat Commun. 2021;12(1):4151.","journal-title":"Nat Commun"},{"issue":"31","key":"3552_CR46","doi-asserted-by":"publisher","first-page":"9374","DOI":"10.1021\/bi0602617","volume":"45","author":"P Wang","year":"2006","unstructured":"Wang P, DeFea KA. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent Inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry. 2006;45(31):9374\u201385.","journal-title":"Biochemistry"},{"issue":"4","key":"3552_CR47","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.21873\/anticanres.15699","volume":"42","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. Treatment outcomes in neuroendocrine prostate cancer. Anticancer Res. 2022;42(4):2167\u201376.","journal-title":"Anticancer Res"},{"issue":"6","key":"3552_CR48","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1007\/s12094-022-03054-9","volume":"25","author":"JM Dai","year":"2023","unstructured":"Dai JM, Sun K, Li C, Cheng M, Guan JH, Yang LN, Zhang LW. Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1\u03b1. Clin Transl Oncol. 2023;25(6):1606\u201316.","journal-title":"Clin Transl Oncol"},{"issue":"32","key":"3552_CR49","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2217\/fon-2020-0095","volume":"16","author":"F Zhang","year":"2020","unstructured":"Zhang F, Cui JY, Gao HF, Yu H, Gao FF, Chen JL, Chen L. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12\/CXCR4 axis. Future Oncol. 2020;16(32):2619\u201333.","journal-title":"Future Oncol"},{"issue":"4","key":"3552_CR50","doi-asserted-by":"publisher","first-page":"e18185","DOI":"10.1111\/jcmm.18185","volume":"28","author":"J Wu","year":"2024","unstructured":"Wu J, Zhang Q, Wu J, Yang Z, Liu X, Lou C, Wang X, Peng J, Zhang J, Shang Z, et al. IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer. J Cell Mol Med. 2024;28(4):e18185.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"3552_CR51","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.3892\/or.2016.4714","volume":"35","author":"J Li","year":"2016","unstructured":"Li J, Guan J, Long X, Wang Y, Xiang X. mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance. Oncol Rep. 2016;35(6):3523\u201331.","journal-title":"Oncol Rep"},{"issue":"8","key":"3552_CR52","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/onc.2016.281","volume":"36","author":"L Hu","year":"2017","unstructured":"Hu L, Li X, Liu Q, Xu J, Ge H, Wang Z, Wang H, Wang Z, Shi C, Xu X, et al. UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy. Oncogene. 2017;36(8):1145\u201356.","journal-title":"Oncogene"},{"issue":"7","key":"3552_CR53","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1541-7786.MCR-11-0592","volume":"10","author":"M Toulany","year":"2012","unstructured":"Toulany M, Lee KJ, Fattah KR, Lin YF, Fehrenbacher B, Schaller M, Chen BP, Chen DJ, Rodemann HP. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res. 2012;10(7):945\u201357.","journal-title":"Mol Cancer Res"},{"key":"3552_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"3552_CR55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/neuonc\/nou058","volume":"16","author":"Q Liu","year":"2014","unstructured":"Liu Q, Turner KM, Alfred Yung WK, Chen K, Zhang W. Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol. 2014;16(10):1313\u201323.","journal-title":"Neuro Oncol"},{"issue":"11","key":"3552_CR56","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-16-2913","volume":"77","author":"Y Ban","year":"2017","unstructured":"Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L, Chouchane L, Ferrari M, Shen H, Ma X. Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. Cancer Res. 2017;77(11):2857\u201368.","journal-title":"Cancer Res"},{"issue":"43","key":"3552_CR57","doi-asserted-by":"publisher","first-page":"e2408598","DOI":"10.1002\/advs.202408598","volume":"11","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Wu Y, Zhao B, Shen Z, Hu S, Zhang C, Zhang X, Zhang J, et al. Blockade of CCR5(+) T cell accumulation in the tumor microenvironment optimizes Anti-TGF-\u03b2\/PD-L1 bispecific antibody. Adv Sci (Weinh). 2024;11(43):e2408598.","journal-title":"Adv Sci (Weinh)"},{"key":"3552_CR58","doi-asserted-by":"crossref","unstructured":"Xie P, Guo L, Yu Q, Zhao Y, Yu M, Wang H, Wu M, Xu W, Xu M, Zhu XD, et al. ACE2 enhances sensitivity to PD-L1 blockade by inhibiting macrophage-induced immunosuppression and angiogenesis. Cancer Res. 2024.","DOI":"10.1158\/0008-5472.c.7627200"},{"issue":"10","key":"3552_CR59","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","volume":"31","author":"X-N Zhang","year":"2021","unstructured":"Zhang X-N, Yang K-D, Chen C, He Z-C, Wang Q-H, Feng H, Lv S-Q, Wang Y, Mao M, Liu Q, et al. Pericytes augment glioblastoma cell resistance to Temozolomide through CCL5-CCR5 paracrine signaling. Cell Res. 2021;31(10):1072\u201387.","journal-title":"Cell Res"},{"issue":"1","key":"3552_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40659-024-00581-3","volume":"58","author":"B Mora-Lagos","year":"2025","unstructured":"Mora-Lagos B, Reyes ME, Lobos-Gonzalez L, del Campo M, Buchegger K, Zanella L, Riquelme I, Ili CG, Brebi P. Maraviroc\/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival. Biol Res. 2025;58(1):4.","journal-title":"Biol Res"},{"issue":"4","key":"3552_CR61","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","volume":"29","author":"N Halama","year":"2016","unstructured":"Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by Anti-CCR5 therapy in cancer patients. Cancer Cell. 2016;29(4):587\u2013601.","journal-title":"Cancer Cell"},{"issue":"9","key":"3552_CR62","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/dmd.119.087684","volume":"47","author":"L Tupova","year":"2019","unstructured":"Tupova L, Ceckova M, Ambrus C, Sorf A, Ptackova Z, Gaborik Z, Staud F. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 transporters: an important role in transplacental pharmacokinetics. Drug Metab Dispos. 2019;47(9):954\u201360.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3552_CR63","doi-asserted-by":"publisher","first-page":"109674","DOI":"10.1016\/j.isci.2024.109674","volume":"27","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Yu SL, Xie ZX, Zhuang RL, Peng SR, Wang Q, Gao Z, Li BH, Xie JJ, Huang H, et al. Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience. 2024;27(5):109674.","journal-title":"iScience"},{"issue":"10","key":"3552_CR64","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y. Molecular events in neuroendocrine prostate cancer development. Nat Reviews Urol. 2021;18(10):581\u201396.","journal-title":"Nat Reviews Urol"},{"issue":"2","key":"3552_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23(2):15.","journal-title":"Curr Oncol Rep"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03552-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:03:57Z","timestamp":1761699837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3552"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03552-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the mice experiments in this study were approved by the Laboratory Animal Use and Care Committee and Research Ethics Committee of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (approval numbers: RA-2020-249 and RJ-2024-198B). The collection of human samples and research conducted was approved by the Medical Ethics Committee of the Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine (approval numbers: KY2023-112-C). Informed consent was obtained from all participating individuals prior to their involvement in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}